Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D02JKY
|
||||
Former ID |
DNCL003080
|
||||
Drug Name |
TD-9855
|
||||
Indication | Pain [ICD9: 338, 356.0, 356.8,780; ICD10:G64, G90.0, R52, G89] | Phase 2 | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Target and Pathway | |||||
Target(s) | Sodium-dependent noradrenaline transporter | Target Info | Modulator | [1] | |
Sodium-dependent serotonin transporter | Target Info | Modulator | [1] | ||
KEGG Pathway | Serotonergic synapse | ||||
NetPath Pathway | TCR Signaling Pathway | ||||
PANTHER Pathway | Adrenaline and noradrenaline biosynthesisP04373:5HT1 type receptor mediated signaling pathway | ||||
5HT2 type receptor mediated signaling pathway | |||||
5HT3 type receptor mediated signaling pathway | |||||
5HT4 type receptor mediated signaling pathway | |||||
Reactome | Na+/Cl- dependent neurotransmitter transporters | ||||
WikiPathways | Monoamine Transport | ||||
NRF2 pathway | |||||
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compoundsWP727:Monoamine Transport | |||||
SIDS Susceptibility Pathways | |||||
Synaptic Vesicle Pathway | |||||
Serotonin Transporter Activity | |||||
References | |||||
REF 1 | Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. Int J Neuropsychopharmacol. 2014 Dec 13;18(2). pii: pyu027. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.